NVS-STG2(HY-157214) is a potent, allosteric small molecule agonist of STING. It binds at the transmembrane domain (TMD) interface of STING, thereby acting as a molecular glue to promote STING oligomerization and contribute to its activation. It may be used in research of STING-related autoimmune diseases.

NVS-STG2(HY-157214) is a potent, allosteric small molecule agonist of STING. It binds at the transmembrane domain (TMD) interface of STING, thereby acting as a molecular glue to promote STING oligomerization and contribute to its activation. It may be used in research of STING-related autoimmune diseases.

NVS-STG2(HY-157214) is a potent, allosteric small molecule agonist of STING. It binds at the transmembrane domain (TMD) interface of STING, thereby acting as a molecular glue to promote STING oligomerization and contribute to its activation. It may be used in research of STING-related autoimmune diseases.

NVS-STG2(HY-157214) is a potent, allosteric small molecule agonist of STING. It binds at the transmembrane domain (TMD) interface of STING, thereby acting as a molecular glue to promote STING oligomerization and contribute to its activation. It may be used in research of STING-related autoimmune diseases.

OTUB2-IN-1 is a specific inhibitor of OTUB2, decreases PD-L1 protein expression in tumor cells, leading to suppressed tumor growth through enhanced infiltration of cytotoxic T lymphocytes (CTLs) within the tumor microenvironment.

OTUB2-IN-1 is a specific inhibitor of OTUB2, decreases PD-L1 protein expression in tumor cells, leading to suppressed tumor growth through enhanced infiltration of cytotoxic T lymphocytes (CTLs) within the tumor microenvironment.

OTUB2-IN-1 is a specific inhibitor of OTUB2, decreases PD-L1 protein expression in tumor cells, leading to suppressed tumor growth through enhanced infiltration of cytotoxic T lymphocytes (CTLs) within the tumor microenvironment.

OTUB2-IN-1 is a specific inhibitor of OTUB2, decreases PD-L1 protein expression in tumor cells, leading to suppressed tumor growth through enhanced infiltration of cytotoxic T lymphocytes (CTLs) within the tumor microenvironment.

Bromoenol lactone((6E)-Bromoenol lactone) is a selective, irreversible, potent inhibitor of calcium-independent phospholipase A2 (iPLA2β) with an IC50 value of ≈7 μM. It prevents antigen-stimulated exocytosis in mast cells without hindering Ca2+ influx.

Bromoenol lactone((6E)-Bromoenol lactone) is a selective, irreversible, potent inhibitor of calcium-independent phospholipase A2 (iPLA2β) with an IC50 value of ≈7 μM. It prevents antigen-stimulated exocytosis in mast cells without hindering Ca2+ influx.